Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone for Diabetic Cardiovascular Autonomic Neuropathy (FibroCAN)
NCT06906081Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cardiovascular autonomic neuropathy (CAN) comparing Finerenone with Placebo (2 arms). Primary endpoint: Change in CART E/I ratio at 78 weeks. Started May 2025; status: recruiting.
02
Drugs
finerenone
03
Conditions
Cardiovascular autonomic neuropathy (CAN)
Beyond the preview
Go deeper on NCT06906081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906081.